Hims said in a separate press release that as part of the deal, it "will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers." The deal ends an ongoing conflict between the two companies over allegations from Novo Nordisk that Hims was distributing copycat versions of its Wegovy weight-loss pill and violating patent protections
(2) batch-specific HPLC chromatogram with resolved peaks for all components
Research has shown GLP-1 medications caused side effects in both groups in the clinical trials and in patients after they entered the market
And sometimes, healing from the inside requires support that goes beyond oral supplements or diet
Across the SURPASS clinical development program, tirzepatide demonstrated clinically meaningful and superior glycated hemoglobin (HbA1c) reductions compared not only with placebo but also with multiple active comparators, including a selective GLP-1RA (Table 1)
However, even among those who regained weight, less than half actually restarted the medication